K
Kurt Zimmermann
Researcher at Bristol-Myers Squibb
Publications - 42
Citations - 1089
Kurt Zimmermann is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Tyrosine kinase & Growth factor receptor. The author has an hindex of 18, co-authored 42 publications receiving 1044 citations. Previous affiliations of Kurt Zimmermann include University of Rochester & Yale University.
Papers
More filters
Journal ArticleDOI
Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor
Joan M. Carboni,Adrian V. Lee,Darryl L. Hadsell,Bruce Rowley,Francis Y.F. Lee,David Bol,Amy Camuso,Marco M. Gottardis,Ann Greer,Ching Ping Ho,Warren Hurlburt,Aixin Li,Saulnier Mark G,Upender Velaparthi,Cindy Wang,Mei-Li Wen,Richard A. Westhouse,Mark D. Wittman,Kurt Zimmermann,Brent A. Rupnow,Tai W. Wong +20 more
TL;DR: A novel animal model that involves transgenic expression of a fusion receptor that is constitutively activated by homodimerization is described that should provide new opportunities for further understanding how aberrant IGF-IR signaling leads to tumorigenesis and for optimizing novel antagonists of the receptor kinase.
Journal ArticleDOI
Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity.
Mark D. Wittman,Joan M. Carboni,Ricardo M. Attar,Balu Balasubramanian,Praveen Balimane,Patrick J. Brassil,Francis Beaulieu,Chiehying Chang,Wendy Clarke,Janet Dell,Jeffrey Eummer,David B. Frennesson,Marco M. Gottardis,Ann Greer,Steven Hansel,Warren Hurlburt,Bruce L. Jacobson,Subramaniam Krishnananthan,Francis Y. Lee,Aixin Li,Tai-An Lin,Peiying Liu,Carl Ouellet,Xiaopeng Sang,Saulnier Mark G,Stoffan Karen M,Yax Sun,Upender Velaparthi,Henry Wong,Zheng Yang,Kurt Zimmermann,Zoeckler Mary Edson,Dolatrai M. Vyas +32 more
TL;DR: Compound 3 (BMS-536924), a novel small-molecule inhibitor of the insulin-like growth factor receptor kinase with equal potency against the insulin receptor is described.
Journal ArticleDOI
Discovery of a 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in clinical development.
Mark D. Wittman,Joan M. Carboni,Zheng Yang,Francis Y.F. Lee,Melissa Antman,Ricardo M. Attar,Praveen Balimane,Chiehying Chang,Cliff Chen,Lorell Discenza,David B. Frennesson,Marco M. Gottardis,Ann Greer,Warren Hurlburt,Johnson Walter Lewis,David R. Langley,Aixin Li,Jianqing Li,Peiying Liu,Harold Mastalerz,Arvind Mathur,Krista Menard,Karishma Patel,John S. Sack,Xiaopeng Sang,Saulnier Mark G,Daniel J. Smith,Kevin Stefanski,George L. Trainor,Upender Velaparthi,Guifen Zhang,Kurt Zimmermann,Dolatrai M. Vyas +32 more
TL;DR: The biological activity, characterization, and SAR leading to 9d (BMS-754807) a small molecule IGF-1R kinase inhibitor in clinical development is described.
Patent
Novel tyrosine kinase inhibitors
Mark D. Wittman,Neelakantan Balasubramanian,Upender Velaparthi,Kurt Zimmermann,Mark G. Saulnier,Peiying Liu,Xiaopeng Sang,David B. Frennesson,Stoffan Karen M,Tarrant James G,Anne Marinier,Stephan Roy +11 more
TL;DR: The present invention provides compounds of Formula (I or (II) that are useful as anti-cancer agents and other diseases that can be treated by inhibiting tyrosine kinase enzymes as discussed by the authors.
Patent
Tyrosine kinase inhibitors
Mark D. Wittman,Neelakantan Balasubramanian,Upender Velaparthi,Kurt Zimmermann,Saulnier Mark G,Peiying Liu,Xiaopeng Sang,David B. Frennesson,Stoffan Karen M,Tarrant James G,Anne Marinier,Stephan Roy +11 more
TL;DR: The formula I compounds are also useful for the treatment of other diseases which can be treated by inhibiting tyrosine kinase enzymes as mentioned in this paper, and they are useful as anti-cancer agents.